Dosage form, especially for muscular balance

DE202025102658U1Undetermined Publication Date: 2026-08-13MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEB GESELLSCHAFT MBH
4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
DE · DE
Patent Type
Utility models
Current Assignee / Owner
MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEB GESELLSCHAFT MBH
Filing Date
2025-05-14
Publication Date
2026-08-13
Patent Text Reader

Abstract

Dosage form, in particular a dietary supplement dosage form (food supplement) or pharmaceutical dosage form, preferably a dietary supplement dosage form (food supplement), in particular for oral administration, preferably a dosage form for use in the maintenance and / or restoration, preferably regulation and / or normalization, of muscle health and / or muscle physiology, wherein the dosage form is designed as a multiphase, in particular at least two-phase, preferably two-phase, dosage form, in particular a tablet, wherein the multiphase, in particular at least two-phase, preferably two-phase, dosage form comprises at least two, preferably (exactly) two, distinct phases, in particular at least two, preferably (exactly) two, distinct layers.with or consisting of different disintegration times and / or release rates when administered orally, wherein a first phase, in particular a first layer, is formed with rapid and / or immediate disintegration and / or release, wherein the first phase, in particular the first layer, comprises at least one cinchona bark extract, in particular dry cinchona bark extract, preferably dry bark extract (Extractum e cortex siccum) of at least one Cinchona species, particularly preferably dry bark extract (Extractum e cortex siccum) of Cinchona pubescens, wherein a second phase, in particular a second layer, is formed with slow and / or delayed (controlled) disintegration and / or release, wherein the first phase and / or the second phase, in particular at least the second phase, preferably the first phase and the second phase,comprising at least one physiologically compatible magnesium compound, in particular a magnesium salt; in particular wherein the first phase and / or the second phase, in particular at least the second phase, preferably the first phase and the second phase, comprises at least one further ingredient selected from the group of B vitamins, D vitamins and K vitamins, as well as combinations or mixtures thereof.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Use of adenosine receptor agonists in therapy

    EP1603576A1

  • Oil separator for vapor compression system compressor

    EP1782002A1

  • Use of adenosine receptor agonists in therapy

    US20060234975A1

  • Use of adenosine receptor agonists in therapy

    WO2004078184A1